Enter multiple symbols separated by commas



  • Johnson & Johnson makes what?!   Wednesday, 20 May 2015 | 8:30 AM ET
    Johnson & Johnson makes what?!

    The consumer products giant makes much more than baby powder. Some of what it sells may surprise you.

  • JNJ CEO: Always on the hunt for new platforms   Wednesday, 20 May 2015 | 8:12 AM ET
    JNJ CEO:  Always on the hunt for new platforms

    Alex Gorsky, Johnson & Johnson chairman & CEO, discusses the company's search for new scientific platforms and potential M&A prospects.

  • JNJ's 'balance approach' accounts for success: CEO   Wednesday, 20 May 2015 | 8:08 AM ET
    JNJ's 'balance approach' accounts for success: CEO

    Alex Gorsky, Johnson & Johnson chairman & CEO, talks about the company's plan to keep its diverse portfolio.

  • Driving innovation in pharma: JNJ CEO   Wednesday, 20 May 2015 | 8:05 AM ET
    Driving innovation in pharma: JNJ CEO

    Alex Gorsky, Johnson & Johnson chairman & CEO, discusses new drugs in the company's pipeline, promising results in oncology, and defending the company's franchise.

  • JNJ expects 10 new drug filings by 2019   Wednesday, 20 May 2015 | 7:30 AM ET
    JNJ expects 10 new drug filings by 2019

    CNBC's Meg Tirrell has the update on JNJ's new drugs announcement, which has a $1 billion potential for each new drug.

  • May 20- Valeant Pharmaceuticals International Inc is in talks to buy Egyptian drugmaker Amoun Pharmaceutical Co to expand its veterinary and human medicines portfolio, Bloomberg reported, citing people familiar with the matter. A sale could value Amoun at $700 million to $800 million, Bloomberg reported. Should Amoun fail to find a buyer, it may consider an...

  • BOSTON, May 19- The now-defunct Massachusetts pharmacy behind a deadly 2012 meningitis outbreak that killed at least 64 people will pay out $200 million to its victims and creditors under a bankruptcy reorganization plan approved on Tuesday. The bankruptcy reorganization plan was approved by U.S. Bankruptcy Court Judge Henry Boroff. Deaths of patients...

  • Valeant CEO expects sharp rise in Asia revenue by 2020 Tuesday, 19 May 2015 | 1:04 PM ET

    MONTREAL, May 19- Valeant Pharmaceuticals International Inc's exposure to Asia's growing middle class could help lead to the quintupling of sales in that market to around $5 billion by 2020, Chief Executive Michael Pearson said on Tuesday. Asia, which is expected to generate about $1 billion in sales this year, "has the best growth prospects of any region in the...

  • Detailed information on the use of medically important antimicrobials- a group of drugs that includes antibiotics, antifungals and antivirals- will help it discern patterns of resistance and identify disease trends, the FDA said in a statement on Tuesday. In an April report on antibiotics that are medically important to humans, the FDA said sales of...

  • May 18- TPG Capital LP may have helped its own campaign to go public after pulling Par Pharmaceutical Holdings Inc's IPO. TPG was preparing to begin an IPO investor roadshow for Par Pharmaceutical Holdings before it agreed to sell the generics drugmaker to Endo International Plc for around $8 billion. Founded in 1992 by David Bonderman and James Coulter, San...

  • Endo International buying Par Pharmaceuticals   Monday, 18 May 2015 | 11:00 AM ET
    Endo International buying Par Pharmaceuticals

    The $8 billion deal comes after a banner year for pharmaceutical deals.

  • Endo buys Par from TPG for $8.05 billion   Monday, 18 May 2015 | 8:02 AM ET
    Endo buys Par from TPG for $8.05 billion

    This will position us as a top-flight generic play in the U.S., says Endo CEO Rajiv De Silva explaining how the acquisition will transform the company.

  • US STOCKS-Futures edge lower ahead of housing data Monday, 18 May 2015 | 7:25 AM ET

    *The National Association of Homebuilders is likely to report that its homebuilders confidence index ticked up to 57 in May from 56 in April. *Endo International's shares rose 3.3 percent to $88.20 in premarket trading after the generic drugmaker said it would buy privately-held Par Pharmaceutical from TPG Capital in a $8.05 billion deal.

  • Cancer breakthrough targets sugar to enhance treatment: HALO CEO

    Helen Torley, Halozyme Therapeutics CEO, discusses a new drug that is disrupting the way cancer patients are treated.

  • May 14- Drug maker Actavis Plc said its Warner Chilcott unit held talks with U.S. government officials to discuss a potential resolution of an investigation into the unit's sales activities, according to a regulatory filing. Warner Chilcott said the company and several of its employees in the sales organization received subpoenas in 2012 from the United...

  • Ranbaxy filed "grossly inadequate" applications seeking approval for its drugs and deceived the FDA into granting approvals and giving the company market exclusivity, the class action lawsuit asserts. The FDA has banned import of drugs from all of Ranbaxy's India- based plants under a wider scrutiny of the country's $15 billion pharmaceutical industry,...

  • Jim O’Neill thinks we need $2B to fund new drugs Thursday, 14 May 2015 | 11:13 AM ET

    As the list of drug-resistant bacteria grows, more research into new antibiotics is needed, according to ex-Goldman Sachs economist Jim O’Neill, who was also made U.K. Commercial Secretary on Thursday.

  • ASCO's immunotherapies update   Thursday, 14 May 2015 | 6:19 AM ET
    ASCO's immunotherapies update

    CNBC's Meg Tirrell takes a look at new cancer-fighting drugs and other therapies in the pipeline.

  • LONDON, May 14- Companies that develop new antibiotics should be awarded prize money of up to $3.5 billion for each new drug, instead of selling the medication at a profit, a review backed by Britain's government said on Thursday. The review, lead by former Goldman Sachs chief economist Jim O'Neill, said the lump sum payments could add up to $16- $37 billion over 10...

  • Biotech to watch ahead of ASCO   Wednesday, 13 May 2015 | 2:36 PM ET
    Biotech to watch ahead of ASCO

    The American Society of Clinical Oncology conference will occur at the end of May in Chicago. CNBC's Meg Tirrell reports which companies investors should watch. Also, Les Funtleyder, ESquared Asset Management, shares his view.